The Francis Crick Institute has launched its first spinout companies aimed at developing novel cancer therapies.
In a press release on 24 October, the Crick said the companies represented the first tangible outcome of the institute’s intention to translate research into treatments.
The first company was co-founded by Adrian Hayday and Oliver Nussbaumer from King’s College London and the Crick. It is called GammaDelta Therapeutics and aims to advance a novel approach to immunotherapy that uses the body’s own T cells.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.